Free Trial

electroCore Q1 2024 Earnings Report

electroCore logo
$15.27 +0.75 (+5.17%)
(As of 12/20/2024 05:31 PM ET)

electroCore EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.50
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

electroCore Revenue Results

Actual Revenue
$5.44 million
Expected Revenue
$5.18 million
Beat/Miss
Beat by +$260.00 thousand
YoY Revenue Growth
N/A

electroCore Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

electroCore Earnings Headlines

HC Wainwright Forecasts Stronger Earnings for electroCore
This Indicator called BOTH NVDA rallies
Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…
NeuroMetrix, Inc.: NeuroMetrix to be Acquired by electroCore
electroCore donates gammaCore Sapphire for real world evalution of nVNS
See More electroCore Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like electroCore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on electroCore and other key companies, straight to your email.

About electroCore

electroCore (NASDAQ:ECOR), a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

View electroCore Profile

More Earnings Resources from MarketBeat

Upcoming Earnings